1061 related articles for article (PubMed ID: 27752710)
21. Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.
Zhang H; Uthman L; Bakker D; Sari S; Chen S; Hollmann MW; Coronel R; Weber NC; Houten SM; van Weeghel M; Zuurbier CJ
Front Cardiovasc Med; 2020; 7():592233. PubMed ID: 33344518
[No Abstract] [Full Text] [Related]
22. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
[TBL] [Abstract][Full Text] [Related]
23. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.
Silva Dos Santos D; Turaça LT; Coutinho KCDS; Barbosa RAQ; Polidoro JZ; Kasai-Brunswick TH; Campos de Carvalho AC; Girardi ACC
Sci Rep; 2023 May; 13(1):8689. PubMed ID: 37248416
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the Na+-H+ exchanger with cariporide abolishes stretch-induced calcium but not sodium accumulation in mouse ventricular myocytes.
Kondratev D; Christ A; Gallitelli MF
Cell Calcium; 2005 Jan; 37(1):69-80. PubMed ID: 15541465
[TBL] [Abstract][Full Text] [Related]
25. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
[TBL] [Abstract][Full Text] [Related]
26. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.
Habibi J; Aroor AR; Sowers JR; Jia G; Hayden MR; Garro M; Barron B; Mayoux E; Rector RS; Whaley-Connell A; DeMarco VG
Cardiovasc Diabetol; 2017 Jan; 16(1):9. PubMed ID: 28086951
[TBL] [Abstract][Full Text] [Related]
27. Adverse postresuscitation myocardial effects elicited by buffer-induced alkalemia ameliorated by NHE-1 inhibition in a rat model of ventricular fibrillation.
Lamoureux L; Radhakrishnan J; Mason TG; Kraut JA; Gazmuri RJ
J Appl Physiol (1985); 2016 Nov; 121(5):1160-1168. PubMed ID: 27633736
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
[TBL] [Abstract][Full Text] [Related]
29. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
[TBL] [Abstract][Full Text] [Related]
30. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
31. N-n-butyl haloperidol iodide inhibits H2O2-induced Na+/Ca2+-exchanger activation via the Na+/H+ exchanger in rat ventricular myocytes.
Huang YP; Gao FF; Wang B; Zheng FC; Zhang YM; Chen YC; Huang ZQ; Zheng YS; Zhong SP; Shi GG
Drug Des Devel Ther; 2014; 8():1257-67. PubMed ID: 25246767
[TBL] [Abstract][Full Text] [Related]
32. Empagliflozin Ameliorates Ouabain-Induced Na
Peng X; Li L; Lin R; Wang X; Liu X; Li Y; Ma C; Ruan Y; Liu N
Cardiovasc Drugs Ther; 2023 Jun; 37(3):461-469. PubMed ID: 34982348
[TBL] [Abstract][Full Text] [Related]
33. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
[TBL] [Abstract][Full Text] [Related]
34. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
36. Implications of the EMPA-REG Trial for Clinical Care and Research.
Stamatouli AM; Inzucchi SE
Curr Diab Rep; 2016 Dec; 16(12):131. PubMed ID: 27812962
[TBL] [Abstract][Full Text] [Related]
37. Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart.
Nishio S; Teshima Y; Takahashi N; Thuc LC; Saito S; Fukui A; Kume O; Fukunaga N; Hara M; Nakagawa M; Saikawa T
J Mol Cell Cardiol; 2012 May; 52(5):1103-11. PubMed ID: 22394624
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficiency of Na+/Ca2+ exchanger or Na+/H+ exchanger inhibition and their combination in reducing coronary reperfusion-induced arrhythmias.
Szepesi J; Acsai K; Sebok Z; Prorok J; Pollesello P; Levijoki J; Papp JG; Varro A; Toth A
J Physiol Pharmacol; 2015 Apr; 66(2):215-26. PubMed ID: 25903952
[TBL] [Abstract][Full Text] [Related]
39. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
40. Intracellular pH regulatory mechanism in human atrial myocardium: functional evidence for Na(+)/H(+) exchanger and Na(+)/HCO(3)(-) symporter.
Loh SH; Chen WH; Chiang CH; Tsai CS; Lee GC; Jin JS; Cheng TH; Chen JJ
J Biomed Sci; 2002; 9(3):198-205. PubMed ID: 12065894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
